Efficacy and Safety of Baricitinib in Japanese Patients with Active Rheumatoid Arthritis Receiving Background Methotrexate Therapy: A 12-week, Double-blind, Randomized Placebo-controlled Study

The Journal of Rheumatology
Y TanakaW Macias

Abstract

To evaluate efficacy and safety, baricitinib [Janus kinase (JAK) 1/JAK2 inhibitor] was compared with placebo in Japanese patients with active rheumatoid arthritis (RA) despite background treatment with methotrexate (MTX). This was a phase IIB, double-blind, randomized, placebo-controlled study (clinicaltrials.gov: NCT01469013). Patients had moderate to severe active adult-onset RA despite stable treatment with MTX. Patients (n = 145) were randomized in a 2:1:1:1:1 ratio to placebo or 1 mg, 2 mg, 4 mg, or 8 mg oral baricitinib daily for 12 weeks. The primary analysis compared the combined 4/8-mg dose groups with placebo for the American College of Rheumatology (ACR) 20 response rate at 12 weeks. Other outcomes included additional measures of disease activity, physical function, laboratory abnormalities, and adverse events. A significantly higher proportion of patients in the combined 4/8-mg baricitinib group (37/48, 77%) compared with the placebo group (15/49, 31%) had at least an ACR20 response after 12 weeks of treatment (p < 0.001). Significant improvements in disease activity, remission, and physical function were observed as early as Week 2 of treatment with baricitinib, particularly with daily doses of ≥ 4 mg. Only 1 patie...Continue Reading

References

May 23, 1998·Annual Review of Immunology·W J Leonard, J J O'Shea
Apr 13, 2005·Autoimmunity Reviews·Yannis Alamanos, Alexandros A Drosos
Mar 18, 2010·Nature Reviews. Rheumatology·Yuta KochiKazuhiko Yamamoto
Apr 7, 2010·The Journal of Immunology : Official Journal of the American Association of Immunologists·Jordan S FridmanKris Vaddi
Nov 19, 2010·Journal of Clinical Rheumatology : Practical Reports on Rheumatic & Musculoskeletal Diseases·Michihiro OgasawaraYoshinari Takasaki
Dec 14, 2011·The New England Journal of Medicine·Iain B McInnes, Georg Schett
Apr 3, 2013·Annals of the Rheumatic Diseases·John J O'SheaArian Laurence
May 14, 2014·Expert Opinion on Investigational Drugs·Peter Norman
Jan 15, 2015·Annual Review of Medicine·John J O'SheaArian Laurence

❮ Previous
Next ❯

Citations

Mar 31, 2016·The New England Journal of Medicine·Mark C GenoveseJosef S Smolen
Jun 3, 2016·Expert Review of Clinical Immunology·Shigeru Iwata, Yoshiya Tanaka
Jul 19, 2016·Expert Review of Clinical Immunology·Satoshi KuboYoshiya Tanaka
Sep 1, 2016·BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy·Shingo NakayamadaYoshiya Tanaka
Oct 4, 2016·Expert Opinion on Pharmacotherapy·Shingo NakayamadaYoshiya Tanaka
Nov 9, 2016·Current Opinion in Immunology·Kiyoshi HiraharaJohn J O'Shea
Feb 16, 2017·The New England Journal of Medicine·Peter C TaylorYoshiya Tanaka
Jul 25, 2017·Expert Opinion on Pharmacotherapy·Christophe RichezBernard Bannwarth
Mar 4, 2018·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Ian C ScottDavid L Scott
Feb 22, 2018·Annals of the Rheumatic Diseases·Peter C TaylorIain B McInnes
Aug 4, 2018·Expert Review of Clinical Pharmacology·Maddalena NapolitanoCataldo Patruno
Feb 1, 2019·The Journal of Dermatological Treatment·Maria Alexandra Rodrigues, Tiago Torres
Nov 19, 2019·Expert Opinion on Investigational Drugs·Jing WuChanghai Ding
Sep 10, 2020·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Heinz-Josef LenzJustin Stebbing
Sep 25, 2020·Expert Opinion on Pharmacotherapy·Thomas El JammalYvan Jamilloux
Mar 16, 2019·Pharmaceuticals·Annie Mayence, Jean Jacques Vanden Eynde
Feb 20, 2020·Journal of Cellular Physiology·Arezoo HosseiniBehzad Baradaran
May 7, 2020·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Saad M Alshahrani, Faiyaz Shakeel
Sep 29, 2020·Journal of Inflammation Research·Robert HarringtonRichard Conway
Jun 5, 2018·BioMed Research International·Przemyslaw J Kotyla
Mar 16, 2017·Drugs·Anthony Markham
Apr 25, 2018·Drugs·Zaina T Al-Salama, Lesley J Scott
Jan 22, 2019·Arthritis & Rheumatology·Peter C TaylorTsutomu Takeuchi
Dec 12, 2018·American Journal of Clinical Dermatology·Helen He, Emma Guttman-Yassky
May 31, 2020·EMBO Molecular Medicine·Justin StebbingUNKNOWN Sacco Baricitinib Study Group

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.